ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Contralateral breast cancer in patients carrying mutations in the BRCA1∕2 gene.
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aim was to offer a better view of breast cancer (BC) in Romanian patients and to identify the most frequent BRCA1∕2 germline mutations in a cohort of Romanian patients with contralateral BC (CBC). This is one of the first comprehensive studies to determine the contribution of BRCA1∕2 germline mutations to CBC development in the Romanian population. PATIENTS, MATERIALS AND
methodsThis is a prospective study and included 281 patients with BC. We established the histological type and immunohistochemical profile for these breast tumors. We identified mutations in the BRCA1∕2 oncogenes in those patients diagnosed with CBC. We investigated correlations between the BRCA1∕BRCA2 genes mutation and the increased risk of collateral BC.
resultsThe most common histological type observed was ductal carcinoma. Our study group of tumors was classified into the following BC subtypes: 84.69% triple-negative BC, 9.60% Luminal A, 3.55% human epidermal growth factor receptor 2 (HER2)-positive and 2.13% Luminal B. Forty-one cases were diagnosed with collateral BC. For these 41 cases, genetic testing was performed for the BRCA1 and BRCA2 genes and we obtained seven cases with negative results and 34 cases with positive results for mutations in the BRCA1 gene, describing the following types of mutations: c.3067.C>T (24 cases - 70.6%), c.5266dupC (four cases - 11.8%), c.4035delA (six cases - 17.6%).
conclusionsThis study offered a better view of BC in Romanian patients and identified the most frequent BRCA1∕2 germline mutations in a cohort of Romanian patients with CBC. Also, these results demonstrate that BRCA1 gene mutations increase the risk for CBC development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.